Ribbon

Mechanically, the payment suspends the liquidation trigger and shifts the redemption window forward by 30 days. Chief Executive Officer Angshuman (Bubai) Ghosh signed the report on June 8, 2026, authorizing the deposit. The filing contains no additional substantive updates: the company makes no claims regarding customers, revenue, market size, technology, strategic partnerships, litigation, or personnel changes, and only reiterates that Class A Ordinary Shares carry a par value of $0.0001 per share.

Loss of the NASDAQ listing severs the standardized public trading channel required for orderly share redemptions and proxy solicitation, increasing the operational friction around trust distribution if the deal fails or extends. Chief Executive Officer Angshuman (Bubai) Ghosh confirmed the Company is engaged in discussions with Nasdaq to promptly resolve the outstanding fees but disclaimed any assurance of maintaining the listing. The registrant operates as a Cayman Islands blank check company with its principal executive office in Tokyo, Japan, suggesting potential cross-jurisdictional administrative or liquidity pressures underlying the exchange fee default. No data on business combinations, target pipelines, revenue, or trust account balances is provided.

The filing reveals significant redemptions reducing trust assets, ongoing extension payments that deplete funds, and a going concern warning if the business combination fails. The promissory note indicates sponsor support. Investors evaluating redemption risk or deal completion timeline need this updated financial picture.

This filing confirms the continued activation of the monthly extension mechanism, pushing the redemption/liquidation trigger forward by one month without forcing a capital call or public offering at this stage. Investors monitoring the extension cadence should track future 8-Ks for subsequent $125,000 deposits or potential shifts in trustee arrangements. The filing discloses no information regarding deal progress, customer metrics, revenue, market positioning, technology partnerships, or litigation, and reports no changes to sponsor conduct or board composition beyond the standard executive attestation of the extension deposit.

Shareholders should update their liquidity and redemption calendars, as capital return or conversion events are deferred by roughly five months. Because the record date was fixed at February 18, 2026, investors acquiring shares post-cutoff will not participate in this specific voting cycle, effectively locking out later-market participants from the associated redemption rights. Beyond this administrative postponement and the executive signature line, the filing contains no substantive claims regarding target customers, revenue streams, market size parameters, operational strategy, proprietary technology, partnership frameworks, active litigation, or personnel transitions. The document functions strictly as a logistical notice that management requires additional proxy-solicitation time rather than forcing an accelerated close, preserving the current capital structure and deferring ultimate disposition until the September session concludes.

Investors tracking redemption deadlines and trust value need to note the redemption event (30% of public shares redeemed) and the extended deadline. The trust per-share value after redemptions is approximately $10.40, but the trust balance is now reduced. The filing confirms the deal is progressing but includes risk factors about completing the business combination. The going concern warning indicates liquidity risk if the deal fails.

The funding extends the sponsor’s timeline without triggering automatic liquidation or early redemptions, preserving the trust corpus against premature dissolution. As stated in the report, the payment was made 'for the benefit of its public shareholders' and was attested by Chief Executive Officer Angshuman (Bubai) Ghosh from the registrant’s Tokyo address. Because the disclosure solely records the mechanical extension deposit, it attributes zero new claims regarding customers, revenue, market size, technology, partnerships, or litigation to management, the board, or target advisors. For investors tracking the redemption calendar and trust mechanics, this confirms iterative sponsor cash contributions rather than dilutive financing events, but the absence of combination-specific disclosures signals no imminent shareholder vote. Market participants should monitor for subsequent 8-K filings confirming each monthly funding tranche and review the underlying extension amendments for any adjustments to termination rights, redemption pricing, or sponsor lock-up terms.

Delaying the shareholder vote postpones the formal approval milestone necessary to close the merger, keeping redemption windows and trust liquidation timelines in suspension. Advancing the meeting to April 13, 2026 without a simultaneous extension declaration or revised trust funding terms introduces procedural uncertainty for investors tracking deal momentum. The sponsor's explicit need for extra solicitation time highlights ongoing efforts to secure voting thresholds ahead of the adjourned session, requiring investors to monitor subsequent proxy tabulations before making final disposition decisions.

This adjournment alters the immediate merger timeline by pausing the shareholder vote to avoid a failed approval threshold that could trigger immediate dissolution and cash redemptions. While the statutory deal completion deadline remains January 16, 2027, the postponement indicates that management requires additional days to gather sufficient voting support before proceeding. Chief Executive Officer Angshuman (Bubai) Ghosh executed the filing, confirming that the February 18, 2026 record date stands unchanged and existing proxies carry forward, effectively extending the active voting window indefinitely until a rescheduled date is publicly set.

In SPAC structures, adjourning a shareholder meeting almost invariably signals that management or the sponsor requires additional shareholder approval to advance a deSPAC transaction, extend the trust termination window, or amend governing documents. This procedural delay keeps redemption windows active and defers capital deployment or return, directly impacting timing relative to the stated January 16, 2027 liquidation horizon. The filing discloses no revenue, customer concentrations, technology roadmap, partnership terms, or litigation. For portfolio managers monitoring trust value and exit mechanics, the key takeaway is timeline extension and proxy dependency; investors should await the supplemental filing listing the rescheduled date and specific ballot measures to evaluate whether the sponsor intends to pursue an extension, amend redemption terms, or accelerate a merger vote before the termination deadline expires.

The filing directly updates the special meeting calendar, pushing the shareholder vote—and any associated redemption or merger approval deadlines—four days later to March 16, 2026. According to Chief Executive Officer Angshuman (Bubai) Ghosh, the delay is intended solely to extend the proxy solicitation period, indicating a continuation of the business combination process rather than a termination or regulatory halt. While the underlying SPAC dissolution deadline of January 16, 2027, and the Trust Account valuation remain unaffected, the extension temporarily prolongs the uncertainty period for public stockholders weighing redemption elections versus holding positions through the rescheduled vote. The document contains no additional commercial disclosures, financial projections, customer metrics, litigation updates, or personnel changes beyond the administrative scheduling notice and executive signature.

This filing materially alters the liability profile surrounding the sponsor while preserving trust account integrity. By contractually subordinating the $600,000 obligation to third-party creditors and completely shielding the trust account, the payee ensures that neither early redemptions nor a potential liquidation would require drawing down the per-share trust balances. Because payment is mechanically triggered only upon business combination closings, the instrument functions as deferred sponsor financing that avoids immediate cash demands and does not accelerate the January 16, 2027 termination deadline. Beyond these structural mechanics, the document contains no commercial forecasts, customer disclosures, revenue projections, technology roadmaps, partnership agreements, or litigation claims. The filing merely establishes the contractual terms governing this specific affiliate advance until a target acquisition closes.

If shareholders reject the amendment, the Company warns it may be forced to liquidate because the Sponsor 'has advised the Company that it does not intend to fund Monthly Contributions in excess of US$50,000 per month,' meaning the prior US$125,000 threshold cannot be met. A lower monthly deposit slows trust accretion, which the Board acknowledges could reduce the eventual per-share redemption amount relative to the original extension framework. On deal progress, the Board confirms a Business Combination Agreement was signed on June 30, 2025 with DRC Medicine Ltd., Pubco, and Merger Sub, but management states additional time is necessary to complete SEC review and satisfy customary closing conditions. Regarding sponsor conduct and conflicts, management discloses the Sponsor paid US$0.0087 per share for 1,250,000 Founder Shares (US$25,000 total) and US$10.00 per unit for 220,000 Private Placement Units (US$2,200,000 total). Based on forward-looking projections outlined by the Board, those Founder Shares could reach a value of approximately US$12.5 million at transaction close, creating a structural incentive for insiders to pursue and close a business combination even if public shareholders receive less favorable terms.

The filing mechanically pushes the deal completion window forward by two consecutive months without requiring a fresh shareholder vote, as the extension fees were pre-authorized. For investors monitoring redemption windows, these cash infusions demonstrate active sponsor participation in maintaining the trust balance through pre-approved paid extensions, signaling continued search activity but also extended execution risk. No new targets, customer contracts, revenue figures, partnership announcements, litigation matters, or strategic pivots are disclosed; the submission serves strictly as a compliance update tracking extension funding and timeline slippage.

This proxy materially recalibrates the economic calculus for public shareholders weighing redemption versus extension. The Board of Directors stated it needs additional time to navigate SEC review of the pending business combination with DRC Medicine Ltd., signed June 30, 2025, which contemplates a share exchange, domestication to Delaware, and merger. According to the filing, because the Sponsor holds 1,250,000 Founder Shares purchased for $25,000 in the aggregate ($0.0087 or $0.008 per share) and 220,000 Private Placement Units at $10.00 per unit for an aggregate purchase price of $2,200,000—none of which carry redemption rights—the Board and Sponsor face total equity loss if the SPAC liquidates, creating a structural incentive to approve extensions and close the transaction even if public shareholders might prefer liquidation. The Company cautioned that reducing the monthly contribution to $50,000 means each extension adds less incremental value to the trust, which could result in a lower per-share redemption amount in a liquidation compared to the previous $125,000 monthly framework. The filing further identifies regulatory and operational risks, noting potential CFIUS scrutiny for U.S. targets due to the Sponsor’s non-U.S. status, uncertainty around the 1 percent stock repurchase excise tax under the Inflation Reduction Act, and the possibility that the Company may liquidate trust holdings into cash to avoid being classified as an unregistered investment company under the Investment Company Act of 1940, which would halt interest accrual and reduce future redemption values. The Board recommended voting 'FOR' both proposals, while proxy solicitor Advantage Proxy is compensated a customary fee of $8,500 plus expenses.

Without this extension, Ribbon Acquisition Corp. would have been required to liquidate and redeem public shares. The extension provides the SPAC an additional year to close a business combination, directly affecting the redemption deadline and trust distribution timeline. Since the SPAC is in a DEAL_ANNOUNCED status, this extension likely provides time to close the announced transaction.

Investors tracking redemption deadlines now have a new deadline of January 16, 2027, providing an additional year for the SPAC to close a deal. The elimination of the $100,000 interest withdrawal for dissolution expenses slightly reduces potential erosion of trust value. The extension was approved by shareholders, indicating sponsor commitment to continue searching for a target. Trust per-share value remains $10.00 as stated in the context.

For redemption-track investors, this filing formally resets the SPAC’s liquidation timeline to January 16, 2027, eliminating imminent expiration risk and establishing a twelve-month runway for merger execution. The disclosed $14,937,325.92 outflow directly reduces the trust corpus, while the mandatory $125,000 monthly infusion creates a predictable accretion schedule that will partially offset future redemption waves or extension requests. Stripping the $100,000 dissolution expense withdrawal right fortifies the residual trust balance, ensuring fewer encumbrances remain on shareholder funds during any hypothetical wind-down. The explicit obligation to 8-K-file each monthly payment guarantees real-time visibility into trust maintenance costs and remaining liquidity, allowing holders to model exact cash-equivalent thresholds and evaluate whether continued holding aligns with their redemption preferences ahead of the new January 16, 2027 cutoff.

This routine compliance exhibit fundamentally alters the SPAC’s capital maintenance mechanics without addressing commercial progress. The removal of the authorization to draw up to US$100,000 of accrued trust interest for dissolution expenses forces all potential wind-down costs onto principal or external capital, while the new $125,000 monthly deposit obligation establishes a fixed carrying cost that reduces net trust growth relative to prior terms. The company’s reported quorum of 4,976,677 shares and consistent 4,811,942-for-vote margins confirm sponsor-aligned proxy consolidation, effectively securing a twelve-month runway through January 16, 2027 subject to Cayman Islands Registrar filing procedures. Because the filing discloses no information regarding target identification, revenue projections, customer contracts, litigation exposure, or board changes, its substantive value lies exclusively in trust covenant restructuring and timeline preservation. Investors modeling liquidation floors should track how the $125,000 monthly erosion interacts with prevailing money-market yields, recognizing that no redemption election data or secondary market sentiment metrics are contained herein.

The approved extension resets the liquidation timeline to January 16, 2027, granting the sponsor twelve additional months to close a merger before trust funds must be distributed or the entity dissolved. Mechanically, the trust fund trajectory shifts: the new $125,000 monthly obligation now flows directly into the trust account rather than depleting it, while eliminating the prior US$100,000 dissolution expense carve-out removes a historical cost-offset mechanism. By contractually binding the Company to file an 8-K for every subsequent monthly deposit, the registrant has instituted a recurring transparency protocol that directly impacts how investors track trust account accretion and calculate redemption floor values leading into the new deadline. Beyond the extension mechanics and governance amendments, the filing contains no disclosures regarding target industry sectors, customer pipelines, projected revenue streams, market capitalization assumptions, proprietary technology, strategic partnerships, active litigation matters, or executive compensation packages.

Investors face a binary choice: approve a funding-dependent extension that raises the trust floor to approximately $10.59 but introduces $125,000/month in unsecured debt reducing post-merger proceeds, or reject the extension and trigger liquidation by January 16, 2026 at the current approximate $10.4069 floor. Approval requires an affirmative vote of at least two-thirds (2/3) of voting shares, and both the Charter and Trust Amendments are legally tethered, meaning rejecting one voids the other. The Board notes public shares closed at approximately $10.34 on December 15, 2025, and warns of insufficient liquidity to sell above redemption price. Insiders hold 1,470,000 votes collectively (including 1,250,000 Founder Shares acquired for $25,000 and 220,000 Private Units bought for $2,200,000), creating a conflict where they could profit even if public shareholders suffer losses. Existing $1,000 in working capital loans and potential CFIUS, Investment Company Act, or Inflation Reduction Act excise tax exposures further complicate the path to a viable transaction.

Board Chairman and CEO Angshuman (Bubai) Ghosh and the directors state the extension is necessary to potentially consummate an initial business combination, though insiders face misaligned incentives: the Sponsor’s 1,250,000 Founder Shares were acquired for $25,000 total ($0.0087 per share) and its 220,000 private units cost $2,200,000, both expiring worthless upon liquidation. The filing discloses outstanding unsecured working-capital loans of $1,000. Risk factors warn that CFIUS review or classification as an unregistered investment company could force liquidation, potentially triggering discretionary cash conversions that halt Trust interest accrual. The Securities and Exchange Commission’s excise tax on stock repurchases may apply to redemptions, payable solely by the Company without accessing the Trust Account. On November 12, 2025, Class A ordinary shares closed at approximately $10.51, though management cautioned that secondary market liquidity remains insufficient to guarantee trades above the redemption floor. Total outstanding ordinary shares numbered 6,470,000 as of September 30, 2025, with the Sponsor and directors collectively controlling voting rights for 1,470,000 shares.

This filing is the first comprehensive financial update since the IPO, providing critical metrics for investors assessing redemption risk and deal viability. The trust value per share is approximately $10.29 (including interest), but the working capital deficit and going concern warning highlight the need for a successful business combination. The detailed terms of the DRC Medicine merger (equity value, consideration mechanics) allow investors to evaluate potential dilution and deal structure. Sponsor share surrender and loan activity provide insight into sponsor alignment. The deadline of January 16, 2026, creates a clear timeline for redemption decisions.

This is the first 10-Q to confirm and detail the announced DRC Medicine deal, giving investors the equity value, the redemption-price-based merger consideration formula, and the proposed Domestication structure. It also provides the trust account balance and reminds holders that the deadline to complete a business combination is January 16, 2026, with the company disclosing substantial doubt about going concern if the deal is not completed in time.

What changed: A Form 8-K Current Report filed by Ribbon Acquisition Corp. under Item 8.01 disclosing a trust account extension payment and resolution of Nasdaq listing compliance. According to the filing, Ribbon Acquisition Corp. deposited an aggregate of $125,000 (the “Extension Payment”) into its trust account for public shareholders, which extends the period to consummate an initial business combination by one month from June 15, 2026 to July 15, 2026. The company further states that, per a letter dated June 9, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, it regained compliance with Nasdaq Listing Rule 5250(f) following payment of a past due fee balance. This formally resolves the non-compliance matter previously outlined in the registrant’s June 5, 2026 8-K filing. The report was executed by Chief Executive Officer Angshuman (Bubai) Ghosh. Why it matters: The $125,000 contribution materially resets the SPAC’s redemption and liquidation calendar, preserving the trust capital and extending shareholder decision windows through July 15, 2026 rather than triggering an immediate default event. By confirming Nasdaq Listing Rule 5250(f) compliance, the filing eliminates an active delisting overhang that carried imminent risk of suspending trades for Class A Ordinary Shares (RIBB), Units (RIBBU), and Rights (RIBBR). Investors consequently face uninterrupted exchange access and retained redemption rights through the revised deadline.

What changed: Form 8-K Current Report filed under Item 8.01 Other Events announcing a trust account extension payment. According to the registrant, an aggregate of $125,000 was deposited into the trust account, extending the period to consummate an initial business combination by one month from May 15, 2026 to June 15, 2026. Why it matters: Mechanically, the payment suspends the liquidation trigger and shifts the redemption window forward by 30 days. Chief Executive Officer Angshuman (Bubai) Ghosh signed the report on June 8, 2026, authorizing the deposit. The filing contains no additional substantive updates: the company makes no claims regarding customers, revenue, market size, technology, strategic partnerships, litigation, or personnel changes, and only reiterates that Class A Ordinary Shares carry a par value of $0.0001 per share.

What changed: SEC Form 8-K Current Report disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard (Item 3.01). On June 4, 2026, Nasdaq’s Listing Qualifications Department issued a staff determination letter notifying Ribbon Acquisition Corp. that it will delist the Company’s securities for failing to pay fees required under Nasdaq Listing Rule 5250(f). According to the Notice, the past-due fee balance currently totals $75,000. The Company plans to appeal to a Hearings Panel, with a hearing request deadline of 4:00 p.m. Eastern Time on June 11, 2026, and a hearing fee of $20,000. An automatic stay of suspension applies pending the Panel's ruling. The filing does not modify or pause the existing January 16, 2027 merger deadline. Why it matters: Loss of the NASDAQ listing severs the standardized public trading channel required for orderly share redemptions and proxy solicitation, increasing the operational friction around trust distribution if the deal fails or extends. Chief Executive Officer Angshuman (Bubai) Ghosh confirmed the Company is engaged in discussions with Nasdaq to promptly resolve the outstanding fees but disclaimed any assurance of maintaining the listing. The registrant operates as a Cayman Islands blank check company with its principal executive office in Tokyo, Japan, suggesting potential cross-jurisdictional administrative or liquidity pressures underlying the exchange fee default. No data on business combinations, target pipelines, revenue, or trust account balances is provided.

What changed: Quarterly report on Form 10-Q for the quarter ended March 31, 2026, filed by Ribbon Acquisition Corp. (RIBB), a SPAC that has announced a business combination with DRC Medicine Ltd. Trust account balance decreased from $51,948,314 to $37,716,530 due to redemption of 1,436,867 public shares at ~$10.40 per share in January 2026. Deadline extended from January 16, 2026 to January 16, 2027, with monthly extension payments of $125,000. Company issued a $600,000 non-interest-bearing promissory note to a shareholder of the sponsor. Working capital deficit of $1,008,960. Net income of $252,755 from interest income. Going concern disclosure updated. No material changes to business combination agreement terms with DRC Medicine. Why it matters: The filing reveals significant redemptions reducing trust assets, ongoing extension payments that deplete funds, and a going concern warning if the business combination fails. The promissory note indicates sponsor support. Investors evaluating redemption risk or deal completion timeline need this updated financial picture.

What changed: Joint Filing Agreement attached to a Schedule 13G beneficial ownership report. The document formalizes an agreement under Rule 13d-1(k) for Westchester Capital Management, LLC, Westchester Capital Partners, LLC, Virtus Investment Advisers, LLC, and The Merger Fund to jointly file a Schedule 13G regarding their holdings in Ribbon Acquisition Corporation’s Ordinary Shares. Executed on May 15, 2026 by CaSaundra Wu (Chief Compliance Officer), Chetram Persaud (Chief Compliance Officer), and Daphne Chisolm (Vice President, Counsel and Assistant Secretary), the text contains no share quantities, acquisition prices, or ownership percentages. Consequently, it introduces no changes to redemption deadlines, trust value mechanics, extension triggers, or sponsor conduct. Why it matters: This exhibit confirms that four institutional vehicles are maintaining active SEC reporting obligations for RIBB during the announced-deal phase. Because the primary Schedule 13G data is omitted from this attachment, the filing does not shift the redemption calendar, adjust trust distributions, or signal lock-up behavior. The joint-filing arrangement reflects coordinated compliance among affiliated managers, which investors watch when assessing potential blockholder alignment or upcoming position disclosures. The document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, personnel changes, or litigation.

What changed: Routine compliance exhibit—a Schedule 13G/A beneficial ownership report. Polar Asset Management Partners Inc. submitted this amended filing to update public records of its security positions. The provided text contains only the filing designation, the SEC accession number, and the holder’s corporate name. It contains no disclosures, proposals, or updates regarding Ribbon’s redemption calendar, trust distribution mechanics, extension votes, business combination timeline, or sponsor conduct. Why it matters: The document attributes no claims to Polar Asset Management Partners Inc. or any other party regarding Ribbon’s operations, financial performance, customer base, market positioning, technology, partnerships, litigation, or leadership. Because the excerpt contains zero commercial, strategic, or structural assertions, it does not modify shareholder redemption rights, alter the deal progression framework, or impact sponsor accountability measures.

What changed: A routine compliance exhibit—specifically, a Schedule 13G beneficial ownership report—filed to register equity holdings in Ribbon (RIBB) by Hudson Bay Capital Management LP and Sander Gerber. The provided filing text contains no disclosures regarding redemption deadline adjustments, trust value per share revisions, extension voting procedures, merger or business combination progress, or sponsor conduct. The only quantifiable identifiers present are the SEC submission tag 0001393825-26-000039 and the filing date 2026-05-12. Why it matters: Although Schedule 13G filings typically mark the crossing of a five-percent beneficial ownership threshold or indicate coordinated investment activity, this excerpt omits share counts, percentage of outstanding class, acquisition purpose language, and amendment indicators. Consequently, it supplies zero evidence of capital deployment shifts, redemption floor mechanics, or transaction timeline modifications. Because the document advances no claims regarding customer contracts, revenue milestones, total addressable market sizing, technology development, partnership formations, litigation exposure, or executive personnel changes, there are no attributed statements to weigh against existing deal parameters. Investors monitoring the SPAC lifecycle must treat this as a baseline regulatory disclosure rather than a catalyst for near-term redemption actions or closing events.

What changed: Amendment No. 1 to Ribbon Acquisition Corporation's Form 10-K for the fiscal year ended December 31, 2025, originally filed March 31, 2026. It is filed solely to add the company's Clawback Policy as Exhibit 97.1. No other change is made, and the amendment expressly does not reflect events after the original filing or modify any disclosure. The cover page states that 4,793,446 ordinary shares were issued and outstanding as of March 31, 2026. Why it matters: This is an exhibit-only housekeeping filing with no economic content: no financial statement, trust balance, deadline or transaction disclosure is amended or updated. Its only significance is compliance, since exchange rules require a listed issuer's annual report to include the compensation recovery policy, and Ribbon has now supplied it. Investors should look to the original March 31, 2026 annual report for anything that bears on trust value or the business-combination timetable, because nothing here changes it.

What changed: A Form 8-K Current Report filed by Ribbon Acquisition Corp. to officially record a monthly trust account contribution that activates a pre-approved extension of the business combination deadline. According to Item 8.01, which was signed by Chief Executive Officer Angshuman (Bubai) Ghosh on behalf of the registrant, an aggregate of $125,000 was deposited into the company’s trust account on April 14, 2026. The filing states this deposit funds a one-month extension of the deadline to consummate the initial business combination, consistent with the Extension Amendment and Trust Amendment previously approved by shareholders. Why it matters: This filing confirms the continued activation of the monthly extension mechanism, pushing the redemption/liquidation trigger forward by one month without forcing a capital call or public offering at this stage. Investors monitoring the extension cadence should track future 8-Ks for subsequent $125,000 deposits or potential shifts in trustee arrangements. The filing discloses no information regarding deal progress, customer metrics, revenue, market positioning, technology partnerships, or litigation, and reports no changes to sponsor conduct or board composition beyond the standard executive attestation of the extension deposit.